Shots: The P-III MYSTIC Trial involves assessing of Imfinzi (durvalumab) as a monothx or Imfinzi plus tremelimumab vs SoC Pt-based CT in patients with EGFR and anaplastic lymphoma kinase (ALK) wild-type, locally-advanced or metastatic Stage IV NSCLC in 167 centers across 17 countries MYSTIC Trial included 1EPs as PFS for combination and OS for monothx […]Read More
